Table 2.
The MSS and ASN (equally-sized groups), and expected number of stops for detecting the joint effects for both endpoints based on the assumption A1 from the PLACIDE clinical trial, with the overall power of 1 − β =0.80 at the one-sided significance level of α =0.025. The critical values are determined by the O’Brien-Fleming testing procedure for both endpoints, with the LD alpha-spending method with equally spaced information time.
| Correlation | Number of analyses |
MSS | ASN | Expected number of stops |
|---|---|---|---|---|
| 0.0 | 2 | 2,232 | 2,099 | 1.88 |
| 3 | 2,250 | 1,950 | 2.60 | |
| 4 | 2,264 | 1,894 | 3.35 | |
| 5 | 2,270 | 1,858 | 4.09 | |
| 0.3 | 2 | 2,220 | 2,056 | 1.85 |
| 3 | 2,238 | 1,921 | 2.58 | |
| 4 | 2,248 | 1,859 | 3.31 | |
| 5 | 2,260 | 1,827 | 4.04 | |
| 0.5 | 2 | 2,212 | 2,030 | 1.84 |
| 3 | 2,226 | 1,899 | 2.56 | |
| 4 | 2,240 | 1,839 | 3.28 | |
| 5 | 2,250 | 1,805 | 4.01 | |
| 0.8 | 2 | 2,200 | 1,997 | 1.82 |
| 3 | 2,220 | 1,879 | 2.54 | |
| 4 | 2,232 | 1,816 | 3.25 | |
| 5 | 2,240 | 1,780 | 3.97 | |
| 0.99 | 2 | 2,200 | 1,993 | 1.81 |
| 3 | 2,214 | 1,872 | 2.54 | |
| 4 | 2,232 | 1,813 | 3.25 | |
| 5 | 2,240 | 1,777 | 3.97 |